# KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome

> **NCT07652879** · PHASE2 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 20 (estimated)

## Conditions studied

- POEMS Syndrome

## Interventions

- **DRUG:** CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE

## Key facts

- **NCT ID:** NCT07652879
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652879, "KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*